Literature DB >> 24281343

What proportion of chronic obstructive pulmonary disease outpatients is eligible for inclusion in randomized clinical trials?

Nicola Scichilone1, Marco Basile, Salvatore Battaglia, Vincenzo Bellia.   

Abstract

BACKGROUND AND
OBJECTIVE: We aimed to explore to what extent an unselected population of chronic obstructive pulmonary disease (COPD) outpatients would be eligible for inclusion in randomized clinical trials (RCTs).
METHODS: Retrospective analysis of the clinical records of outpatient subjects with an ascertained diagnosis of COPD. COPD outpatients were assessed against the following inclusion criteria: 40 < age < 80 years, current or former smokers, forced expiratory volume in the first second (FEV1) <70% predicted, no long-term oxygen therapy, no other concomitant lung diseases and absence of major extrapulmonary comorbidities. The study consisted of 2 phases; in phase 1, the criteria for inclusion in RCTs on COPD were selected, and in phase 2, the above criteria were applied to an unselected outpatient COPD population.
RESULTS: A total of 578 subjects (83% of the whole group) failed at least one of the inclusion criteria. Lung diseases other than COPD (occurring in 30% of our population, mostly bronchiectasis), long-term oxygen therapy (31%), FEV1 (19%), age (14%) and extrapulmonary comorbidities such as cognitive impairment (14%), arrhythmias (17%) and congestive heart disease (13%) would have been the most frequent causes for exclusion from RCTs.
CONCLUSIONS: In real-life settings, more than 80% of COPD subjects are currently treated by protocols based on results of RCTs for which they would not have been eligible. We encourage a more extensive use of pragmatic trials in COPD to better modulate the application of results of RCTs to patients encountered in daily practice.
© 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2013        PMID: 24281343     DOI: 10.1159/000355082

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  20 in total

1.  How does a clinical trial fit into the real world? The RELAX-AHF study population into the EAHFE registry.

Authors:  Òscar Miró; Víctor Gil; Christian Müller; Alexander Mebazaa; Héctor Bueno; Francisco Javier Martín-Sánchez; Pablo Herrero; Javier Jacob; Pere Llorens
Journal:  Clin Res Cardiol       Date:  2015-04-24       Impact factor: 5.460

Review 2.  Pharmacological Management of Elderly Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome: Room for Speculation?

Authors:  Daniela Castiglia; Salvatore Battaglia; Alida Benfante; Claudio Sorino; Nicola Scichilone
Journal:  Drugs Aging       Date:  2016-06       Impact factor: 3.923

3.  Recommendations to Facilitate Expanded Access to Investigational Therapies for Seriously Ill Patients.

Authors:  Rebecca N Jerome; Terri L Edwards; Haley C Boswell; Gordon R Bernard; Paul A Harris; Jill M Pulley
Journal:  Acad Med       Date:  2016-03       Impact factor: 6.893

4.  Tiotropium Respimat(®) vs. HandiHaler(®): real-life usage and TIOSPIR trial generalizability.

Authors:  Sven Schmiedl; Rainald Fischer; Luisa Ibanez; Joan Fortuny; Petra Thürmann; Elena Ballarin; Pili Ferrer; Monica Sabaté; Dominik Rottenkolber; Roman Gerlach; Martin Tauscher; Robert Reynolds; Joerg Hasford; Marietta Rottenkolber
Journal:  Br J Clin Pharmacol       Date:  2015-12-23       Impact factor: 4.335

Review 5.  Comorbid Influences on Generic Health-Related Quality of Life in COPD: A Systematic Review.

Authors:  Manuel B Huber; Margarethe E Wacker; Claus F Vogelmeier; Reiner Leidl
Journal:  PLoS One       Date:  2015-07-13       Impact factor: 3.240

6.  Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.

Authors:  Peter Kardos; Sally Worsley; Dave Singh; Miguel Román-Rodríguez; David E Newby; Hana Müllerová
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-11-25

7.  Eligibility of real-life patients with COPD for inclusion in RCTs: a commentary.

Authors:  Salvatore Battaglia; Nicola Scichilone
Journal:  Respir Res       Date:  2017-01-05

8.  Real-life effectiveness and safety of salbutamol Steri-Neb™ vs. Ventolin Nebules® for exacerbations in patients with COPD: Historical cohort study.

Authors:  David B Price; Eran Gefen; Gokul Gopalan; Rosie McDonald; Vicky Thomas; Simon Wan Yau Ming; Emily Davis
Journal:  PLoS One       Date:  2018-01-24       Impact factor: 3.240

Review 9.  The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis.

Authors:  Paola Rogliani; Maria Gabriella Matera; Josuel Ora; Mario Cazzola; Luigino Calzetta
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-12-05

10.  Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy.

Authors:  David M G Halpin; Marjan Kerkhof; Joan B Soriano; Helga Mikkelsen; David B Price
Journal:  Respir Res       Date:  2016-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.